What will the future of transthyretin amyloid cardiomyopathy (ATTR-CM) care look like? Dr. Frederick Ruberg joins us to share his perspective on the advances that may shape the next phase of patient care, from screening and therapeutic strategies to expanded genetic testing aimed at identifying patients earlier. He's the Chief of Cardiovascular Medicine at Boston Medical Center and Thomas J. Ryan Professor of Cardiovascular Medicine at Boston University Chobanian and Avedisian School of Medicine.

In women, hypertension follows a distinct biological and clinical course that evolves across reproductive and menopausal transitions, but its long-term implications remain underrecognized and undertreated. In this expert-led discussion, Dr. Shelina Ramnarine and Dr. Payal Kohli examine key considerations in managing hypertension in women and explore practical strategies to improve risk assessment and patient education. Dr. Kohli is an Associate Adjunct Professor at Johns Hopkins University and Duke University, as well as the Founder and Medical Director of Cherry Creek Heart in Aurora, Colorado.

This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.

With increasing recognition and more accessible diagnostic tools, ATTR-CM can no longer be overlooked in patients with atypical heart failure presentations. Dr. Valmiki Maharaj shades insights on connecting clinical clues, confirming diagnosis efficiently, and acting earlier to meaningfully impact long-term outcomes. He's the Director of the Heart Failure Clinic, the Cardiac Amyloidosis Clinic, and the Cardiovascular Disease Fellowship Program at the University of Minnesota Medical School.

Even with growing awareness of transthyretin amyloid cardiomyopathy (ATTR-CM), delays in diagnosis remain a significant challenge. That's why Dr. Ronald Witteles, Professor of Cardiovascular Medicine at Stanford Medicine and Co-Director of the Stanford Amyloid Center, joins us to share practical strategies for recognizing ATTR-CM, implementing the appropriate diagnostic pathway, and overcoming common testing pitfalls.

What clinical clues should raise suspicion for transthyretin amyloid cardiomyopathy (ATTR-CM)? Find out as Dr. Ronald Witteles examines the cardiac and extracardiac manifestations that can help us recognize this often-overlooked disease. He's a Professor of Cardiovascular Medicine at Stanford Medicine and the Co-Director of the Stanford Amyloid Center and Multidisciplinary Sarcoidosis Program.

When blood pressure remains uncontrolled despite treatment, adding more medications may not address the underlying cause. In this expert-led discussion, Drs. Jan Basile and Michael Bloch join Dr. Steve Jackson to examine often-overlooked drivers of hypertension, including aldosterone excess, volume overload, medication adherence, and blood pressure measurement challenges. Learn how a deeper understanding of these drivers can help us distinguish resistant hypertension from pseudo-resistance and individualize treatment decisions for our patients. Dr. Basile is a Professor in the Division of Cardiology at the Medical University of South Carolina in Charleston. Dr. Bloch is a Clinical Assistant Professor in the Department of Internal Medicine at the University of Nevada School of Medicine and the Medical Director of Vascular Medicine and Anticoagulation Services at the Renown Institute for Heart and Vascular Health in Reno.

This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.

Patients with transthyretin amyloid cardiomyopathy (ATTR-CM) often experience significant quality of life challenges that extend beyond cardiac symptoms, including reduced mobility, fatigue, mood changes, and loss of independence. Dr. Kevin Shah discusses practical, patient-centered strategies to identify functional limitations, support emotional well-being, engage caregivers, and align treatment goals with what matters most to these patients. Dr. Shah is an Advanced Heart Failure and Transplant Cardiologist at Long Beach Memorial Hospital, as well as an Associate Professor of Medicine at the University of California Irvine School of Medicine.

Hypertension is a key modifiable cardiovascular risk factor, but its prevalence, progression, and outcomes vary significantly across patient populations. In this program, Dr. Alexandria May and Dr. Keith Ferdinand discuss how social drivers of health, geography, access to care, and comorbid conditions can influence risk and outcomes. Tune in to find out how we can better address variation in hypertension across patient groups. Dr. Ferdinand is the Gerald S. Berenson Chair in Preventive Cardiology and the Director of Preventive Cardiology at Tulane University School of Medicine in New Orleans.

This episode is sponsored by Mineralys Therapeutics Inc. Medical Affairs.

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder that can severely disrupt triglyceride metabolism and place patients at risk for life-threatening complications like acute pancreatitis. Tune in to hear Dr. Robert Eckel in conversation with Dr. Steve Jackson as they break down the key cardiometabolic risks of FCS and how emerging therapies are changing the outlook for patients living with this complex disease. Dr. Eckel is a Professor of Medicine Emeritus at the University of Colorado Anschutz Medical Campus, with appointments in endocrinology, metabolism and diabetes, and cardiology.

The field of sports cardiology has experienced remarkable growth, with new guidelines, expanding programs, and increasing recognition of cardiovascular risk in athletes. Hear from Dr. Jeffrey Hsu as he shares current and emerging approaches to risk assessment, prevention, and management of cardiac conditions in this population. Dr. Hsu is a Clinical Assistant Professor of Medicine at the David Geffen School of Medicine at UCLA, and he spoke about this topic at the 2026 American College of Cardiology (ACC) Scientific Sessions.